SCHEMBL28043777

SCHEMBL28043777

CCCCc1c(N)nc(N)nc1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.51
ADORA1 P30542 2/20 0.51
TLR8 Q9NR97 3/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
IKBKB O14920 1/20 0.45
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
DPP4 P27487 1/20 0.43
BRD4 O60885 1/20 0.42
HEXA P06865 1/20 0.40
HEXB P07686 1/20 0.40
TLR7 Q9NYK1 1/20 0.40
DHFR P00374 1/20 0.40
KDM1A O60341 1/20 0.39
MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL264739 0.81 ADORA2A (0.58) ADORA2AADORA1CYP1A2CYP3A4CYP2D6
SCHEMBL28043769 0.81 DHFR (0.54) ADORA2AADORA1TLR8DPP4DHFR
SCHEMBL16703412 0.80 HEXA (0.51) TLR8CYP2D6DPP4HEXAHEXB
Hydrochloric Acid SCHEMBL20421687 0.77 TLR8 (0.48) TLR8CYP2D6DHFR
SCHEMBL28267182 0.76 ADORA2A (0.56) ADORA2AADORA1TLR8CYP1A2CYP3A4
SCHEMBL12137690 0.76 CYP1A2 (0.56) ADORA2AADORA1CYP1A2CYP3A4CYP2D6
SCHEMBL1357943 0.76 ADORA2A (0.58) ADORA2AADORA1CYP1A2CYP3A4CYP2D6
SCHEMBL12137475 0.75 ADORA2A (0.64) ADORA2AADORA1CYP1A2CYP3A4CYP2D6
SCHEMBL28043944 0.74 HEXA (0.50) ADORA2AADORA1TLR8CYP2D6HEXA
SCHEMBL1358006 0.74 ADORA2A (0.56) ADORA2AADORA1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105143206-A Pyrimidine-2,4-diamine derivatives for treatment of cancer THOMAS HELLEDAYS STIFTELSE F R MEDICINSK FORSKNING 2015-12-09 CN disclosed